智通财经APP讯,万泰生物(603392.SH)披露2026年半年度报告,报告期公司实现营业收入10.48亿元,同比增长24.29%;归属于上市公司股东的净利润亏损1.28亿元,同比收窄;扣非净利润亏损1.69亿元,同比收窄;基本每股收益-0.10元。
营业收入增长,主要是九价HPV疫苗上市后持续推进终端准入销售放量,疫苗板块营业收入较上年同期增加。归属于上市公司股东的净利润较上年同期亏损有所收窄,原因同上述营业收入影响因素。
智通财经APP讯,万泰生物(603392.SH)披露2026年半年度报告,报告期公司实现营业收入10.48亿元,同比增长24.29%;归属于上市公司股东的净利润亏损1.28亿元,同比收窄;扣非净利润亏损1.69亿元,同比收窄;基本每股收益-0.10元。
营业收入增长,主要是九价HPV疫苗上市后持续推进终端准入销售放量,疫苗板块营业收入较上年同期增加。归属于上市公司股东的净利润较上年同期亏损有所收窄,原因同上述营业收入影响因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.